Question of non-inferiority looks a little muddy (twittersphere says p44 is the one to read). However, the BSI sub-population looks relatively strong, and the the drug could be approved for that population based on the LPAD pathway, for which this is a test case with read through to other players. Such as PRTK, in which I have a position, TTPH, others. I used to have one in AKAO, which is reacting mildly well to the release of the docs.
News 
Market Data 
Discover 
AI
